Dr. Rizvi on Utilizing Molecular Characteristics to Inform Treatment Decisions in NSCLC

Naiyer A. Rizvi, MD, discusses treatment approaches in non–small cell lung cancer.

Naiyer A. Rizvi, MD, Price Family ​Professor of ​Medicine, director, Thoracic Oncology, co-director, Cancer Immunotherapy, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, research director, Price Family Comprehensive Center for Chest Care, NewYork-Presbyterian Hospital, discusses treatment approaches in non–small cell lung cancer (NSCLC). 

​Therapy for patients with NSCLC should be individualized ​and selected based on molecular ​abnormalities and PD-L1 status, says Rizvi.

However, patients with high PD-L1 expression and an EGFR mutation should receive targeted therapy rather than immunotherapy as oncogenic drivers are preferred to PD-L1 status, Rizvi explains. 

Moreover, in an era where numerous plasma​-based assays are receiving regulatory approval, molecular data should be thoroughly evaluated to inform treatment decisions before they are made, Rizvi concludes. 

Related Videos
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Marc-Oliver Grimm, MD
Chun Chao, PhD, MS
Mikkael A. Sekeres, MD
Noa Biran, MD
Ranee Mehra, MD, professor, medicine, medical oncology; director, Head and Neck Medical Oncology, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical System
Sumanta Kumar Pal, MD, FASCO, chair, Kidney and Bladder Cancer Disease Team; co-director, Kidney Cancer Program; professor, vice chair, Academic Affairs, Department of Medical Oncology & Therapeutics Research, City of Hope
Alfred L. Garfall, MD, MS
David Braun, MD, PhD